Manulife (Manufacturers Life Insurance)’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.18M Sell
39,660
-36
-0.1% -$1.08K ﹤0.01% 1748
2025
Q4
$1.52M Sell
39,696
-4,933
-11% -$160K ﹤0.01% 1649
2025
Q3
$1.07M Buy
44,629
+527
+1% +$9.91K ﹤0.01% 1822
2025
Q2
$653K Buy
44,102
+2,613
+6% +$43.3K ﹤0.01% 2040
2025
Q1
$743K Buy
41,489
+14,151
+52% +$287K ﹤0.01% 1944
2024
Q4
$476K Sell
27,338
-19,707
-42% -$349K ﹤0.01% 2270
2024
Q3
$658K Buy
47,045
+17,931
+62% +$187K ﹤0.01% 2134
2024
Q2
$239K Buy
29,114
+264
+0.9% +$1.78K ﹤0.01% 2525
2024
Q1
$222K Sell
28,850
-8,352
-22% -$70.5K ﹤0.01% 2547
2023
Q4
$334K Sell
37,202
-241
-0.6% -$1.75K ﹤0.01% 2356
2023
Q3
$335K Buy
37,443
+7,924
+27% +$112K ﹤0.01% 2316
2023
Q2
$453K Buy
29,519
+4,890
+20% +$89K ﹤0.01% 2103
2023
Q1
$554K Buy
24,629
+169
+0.7% +$3.59K ﹤0.01% 1951
2022
Q4
$514K Sell
24,460
-519,329
-96% -$11M ﹤0.01% 1971
2022
Q3
$13.4M Sell
543,789
-504
-0.1% -$13K 0.01% 705
2022
Q2
$13.2M Buy
544,293
+247
+0% +$6.21K 0.01% 731
2022
Q1
$14M Sell
544,046
-5,442
-1% -$144K 0.01% 777
2021
Q4
$16.9K Sell
549,488
-156,437
-22% -$4.41M 0.01% 719
2021
Q3
$17.1M Sell
705,925
-3,577
-0.5% -$65.7K 0.01% 718
2021
Q2
$10.4M Sell
709,502
-1,600,385
-69% -$31.6M 0.01% 948
2021
Q1
$57.7M Buy
2,309,887
+123,057
+6% +$3.4M 0.05% 339
2020
Q4
$59.6M Sell
2,186,830
-24,311
-1% -$568K 0.06% 307
2020
Q3
$40.8M Buy
2,211,141
+29,791
+1% +$579K 0.04% 362
2020
Q2
$43M Sell
2,181,350
-163,067
-7% -$2.6M 0.04% 342
2020
Q1
$34.2M Buy
2,344,417
+1,685
+0.1% +$25.4K 0.04% 354
2019
Q4
$33.3M Sell
2,342,732
-979
-0% -$12.5K 0.04% 414
2019
Q3
$27.8M Buy
2,343,711
+206,908
+10% +$3.42M 0.03% 457
2019
Q2
$42.9M Buy
2,136,803
+192,515
+10% +$3.8M 0.05% 347
2019
Q1
$44M Buy
1,944,288
+73,284
+4% +$1.62M 0.05% 340
2018
Q4
$42.3M Buy
1,871,004
+25,601
+1% +$637K 0.05% 330
2018
Q3
$53M Buy
1,845,403
+327,194
+22% +$9.35M 0.06% 314
2018
Q2
$41.4M Buy
1,518,209
+1,488,347
+4,984% +$39.6M 0.05% 394
2018
Q1
$668K Buy
29,862
+222
+0.7% +$5.29K ﹤0.01% 2118
2017
Q4
$626K Buy
29,640
+615
+2% +$14.1K ﹤0.01% 2173
2017
Q3
$723K Sell
29,025
-1,052
-3% -$23.2K ﹤0.01% 2013
2017
Q2
$583K Buy
30,077
+1,733
+6% +$31.4K ﹤0.01% 2174
2017
Q1
$524K Buy
28,344
+3,362
+13% +$65.8K ﹤0.01% 2150
2016
Q4
$473K Sell
24,982
-20
-0.1% -$409 ﹤0.01% 2137
2016
Q3
$559K Buy
25,002
+49
+0.2% +$933 ﹤0.01% 2010
2016
Q2
$445K Buy
24,953
+1,794
+8% +$29K ﹤0.01% 2113
2016
Q1
$310K Buy
23,159
+192
+0.8% +$2.91K ﹤0.01% 2292
2015
Q4
$443 Buy
22,967
+245
+1% +$4.89K ﹤0.01% 2089
2015
Q3
$460 Buy
22,722
+560
+3% +$16.6K ﹤0.01% 2053
2015
Q2
$735 Buy
22,162
+7,721
+53% +$211K ﹤0.01% 1862
2015
Q1
$346 Sell
14,441
-27
-0.2% -$412 ﹤0.01% 2326
2014
Q4
$177 Buy
14,468
+365
+3% +$3.78K ﹤0.01% 2727
2014
Q3
$127 Buy
14,103
+460
+3% +$5.41K ﹤0.01% 2961
2014
Q2
$160K Buy
+13,643
New +$185K ﹤0.01% 2893

Other funds holding TVTX

Manulife (Manufacturers Life Insurance)'s TVTX Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) reduced its Travere Therapeutics (TVTX) stake by 0.09% in Q1 2026, selling an estimated $1.08K and leaving 39,660 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #1748.

Manulife (Manufacturers Life Insurance) first reported a position in TVTX in Q2 2014 and has held it in 48 quarters since. The position peaked at $59.6M in Q4 2020. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 39,660 shares of Travere Therapeutics worth $1.18M as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) sold 36 Travere Therapeutics shares in Q1 2026, an estimated $1.08K.
  • Travere Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #1748 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Travere Therapeutics in Q2 2014 and has held it in 48 quarters since.
  • Manulife (Manufacturers Life Insurance)'s Travere Therapeutics position peaked at $59.6M in Q4 2020.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.